Sign In
Buy OGN
$13.56
+0 (+0%)
At Close: Aug 04, 2026
Organon & Co. (OGN) Q4 2023 Earnings Call Transcript
12:06pm, Thursday, 15'th Feb 2024
Organon & Co. (OGN) Q4 2023 Earnings Call Transcript
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
12:01pm, Thursday, 15'th Feb 2024
While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
07:30am, Thursday, 01'st Feb 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release fourth quarter and full year 2023 financial results on February 15, 2024, and hold a webcast and conference call at 8:30 AM EST.
Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
10:55pm, Tuesday, 09'th Jan 2024
Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Organon: What I'm Looking For In This 8% Yield In 2024
08:10am, Wednesday, 03'rd Jan 2024
Organon, a pharmaceutical company, has a diverse portfolio of products in women's health and biosimilars. The company has faced challenges in its women's health segment but expects a turnaround in its
11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria
10:18am, Wednesday, 27'th Dec 2023
Investors have different approaches to stock dividends. Some have no interest in current income and would prefer companies to focus on growing their businesses, rather than distributing cash to shareh
High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
10:22am, Tuesday, 19'th Dec 2023
Organon's stock has declined 32% since September, making it one of the worst performers in healthcare. The company reported mixed financial results, with 1% growth in product sales and a decline in to
Jenny Harrington's top dividend picks for 2024: OGN, NYCB, WHR, CWEN, OKE, CCI and STX
04:46pm, Tuesday, 12'th Dec 2023
Jenny Harrington, Gilman Hill Asset Management CEO, discusses her top dividend picks for 2024.
Organon: It's Darkest Before The Dawn
02:52am, Thursday, 30'th Nov 2023
Organon is a global healthcare company focused on women's health, with a diverse portfolio of prescription therapies and medical devices. OGN stock has been on a downward trend due to declining sales
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?
09:53am, Tuesday, 21'st Nov 2023
It has been over two years since Organon spun off from Merck. Lack of growth and deteriorating financials haven't given investors much of a reason to be bullish thus far.
Organon & Co (OGN) Q3 2023 Earnings Call Transcript
12:21pm, Thursday, 02'nd Nov 2023
Organon & Co (NYSE:OGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D C
Organon: The Federal Reserve Black Swan (Rating Upgrade)
11:45am, Wednesday, 04'th Oct 2023
The stock of junk-rated Organon & Co. has lost more than 40% since my first article, largely due to interest rates continuing to rise. I take a close look at the company's debt and how I think the sit
6% Yield And Significantly Undervalued: A Closer Look At Organon
02:23am, Sunday, 10'th Sep 2023
Organon & Co. stock is down 30% year-to-date and 40% below its 52-week highs. OGN offers a dividend yield of 5.8%, making it an attractive option for income-oriented investors. The company has a stabl
S&P Gains and Losses Today: Bank Stocks Tumble on Moody's Downgrade
05:30pm, Tuesday, 08'th Aug 2023
The S&P 500 dipped 0.4% on Tuesday, Aug. 8, 2023, as bank stocks lost ground after Moody's downgrades.
Organon & Co (OGN) Q2 2023 Earnings Call Transcript
12:18pm, Tuesday, 08'th Aug 2023
Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Con
